Pharmacogenomic studies have shown that ADCY9 genotype determines the effects of the CETP (cholesteryl ester transfer protein) inhibitor dalcetrapib on cardiovascular events and atherosclerosis imaging. The underlying mechanisms responsible for the interactions between ADCY9 and CETP activity have not yet been determined. 
H
igh-density lipoproteins (HDL) have multiple potentially protective cardiovascular effects, including those on reverse cholesterol transport, endothelial function, and inflammation.
1 CETP (cholesteryl ester transfer protein) mediates the exchange of cholesteryl esters from HDL to ApoB (apolipoprotein B)-containing lipoproteins. CETP inhibitors have yielded variable results in large clinical trials, which include the recent report from the REVEAL study (Randomized Evaluation of the Effects of Anacetrapib Through Lipid-modification). [2] [3] [4] [5] [6] The pharmacogenomic analysis of the dal-Outcomes trial showed that patients with the AA genotype at rs1967309 in the ADCY9 gene benefited from a 39% reduction in cardiovascular events when treated with dalcetrapib compared to placebo, and these results were supported by atherosclerosis regression on imaging. 5 Furthermore, patients bearing the protective ADCY9 genotype had a large increase in cholesterol efflux when treated with dalcetrapib, and no increase in the inflammation biomarker C-reactive protein; the latter in contrast to results obtained with all CETP inhibitors when administered to unselected populations. 7 The significant ADCY9 gene-by-treatment arm interaction and the lack of ADCY9 genotype-dependent effect in the placebo group suggest a pharmacogenomic effect. The underlying mechanisms responsible for the interaction between ADCY9 and CETP activity have not yet been determined. The opposing genotype-dependent differences in body weight and atherosclerosis-related outcomes in dalcetrapib clinical trials, along with the role of ADCY9 in adrenergic signal transduction, 8 suggest that the autonomic nervous system (ANS) might be involved in the observed effects. ADCY9 encodes adenylate cyclase type 9, an enzyme producing the ubiquitous second messenger cAMP. Therefore, in this investigation we studied the effects of Adcy9 inactivation on atherosclerosis and related processes in the absence or presence of CETP in mice.
METHODS
The data, analytic methods, and study materials will be made available on request.
Animals
Adcy9 gene-trapped (Adcy9 Gt/Gt ) mice were generated initially from Lexicon Pharmaceuticals. 9 Cryo-preserved sperm from the B6;129S5-Adcy9 Gt(neo)159Lex /Mmucd strain was imported from the Mutant Mouse Regional Resource Center (MMRRC) and used for in vitro fertilization and oviduct transfer at the Institute for Research in Immunology and Cancer (IRIC) animal facility in a specific-pathogen-free area and their breeding and reproduction was approved by the University de Montréal Deontology Committee on Animal Experimentation. MaxBax accelerated backcrossing and genotyping (Charles River, Sherbrooke, Quebec, Canada) was performed to achieve >98.6% C57BL/6J genetic background. Procedures involving mice were performed at the Montreal Heart Institute Research Center and approved by the local ethics committee for animal research in accordance with the Canadian Council on Animal Care guidelines. Adcy9
Gt/Gt mice were bred by mating Adcy9
WT/Gt animals. Mice hemizygous for transgenic human CETP minigene (CETPtgAdcy9 WT ), 10 line B6.CBA-Tg(CETP)5203Tall/J, were obtained from The Jackson Laboratory (Bar Harbor, ME) and were on 100% C57BL/6J genetic background. To obtain mice that were both transgenic for CETP and with homozygous inactivation for Adcy9 (CETPtgAdcy9 Gt/Gt ), CETPtgAdcy9
WT mice were first crossed with Adcy9 WT/Gt animals, then mice transgenic for CETP and heterozygote for Adcy9
WT/Gt were crossed with Adcy9 Gt/Gt or Adcy9 WT/Gt animals. All mice were under a C57BL/6J background, males and aged 8 to 12 weeks. Blood collection was performed after 4 hours of fasting.
Atherosclerosis Model

Wild-type (WT), Adcy9
Gt/Gt , CETPtgAdcy9
WT , and CETPtgAdcy9
Gt/Gt male mice were injected with a single dose
Clinical Perspective
What Is New?
• The clinical benefits of the CETP (cholesteryl ester transfer protein) inhibitor dalcetrapib depend on ADCY9 genotype.
• Using a mouse atherosclerosis model inactivated for
Adcy9, we demonstrate that loss of Adcy9 protects from atherosclerosis and is associated with improved endothelial function but only in absence of CETP.
• Adcy9 inactivation increases weight gain, adipose tissue volume and feed efficiency (the latter reflecting altered autonomic tone) in the absence of CETP only. • This mouse model reproduces the interactions between ADCY9 and CETP activity observed in patients and offers new mechanistic insights for the importance of ADCY9 in determining the responses to CETP inhibition.
What Are the Clinical Implications?
• Our preclinical results delineating the atheroprotective effects of Adcy9 inactivation that disappear in the presence of CETP activity strengthen the pharmacogenomic findings from clinical studies.
• The ADCY9 genotype was indeed shown to determine clinical responses to dalcetrapib in terms of cardiovascular events and atherosclerosis changes.
• The Dal-GenE clinical trial is currently testing prospectively whether patients with coronary disease and the favorable ADCY9 genotype will benefit from dalcetrapib. • This trial holds the potential to modify clinical practice by showing that precision medicine can predict the patients who would benefit from specific therapy against atherosclerosis. 
Quantification of Adcy9 mRNA Expression by Reverse TranscriptionQuantitative PCR
Mice total RNA were extracted from heart ventricles and epididymal adipose tissue using RNeasy and RNeasy lipid tissue isolation kits, respectively (QIAGEN, Toronto, ON, Canada), with the DNase I procedure, according to the manufacturer's protocol. cDNA was synthesized with components from High-Capacity cDNA Reverse transcription Transcription kits (Applied Biosystems #4368814, Foster City, CA) and with the use of MultiScribe Reverse Transcriptase, according to the manufacturer's procedures. RNA quantification and quality were assessed using Agilent RNA 6000 Nano Kit for Bioanalyzer 2100 System (Agilent Technologies, Santa Clara, CA). Primers were designed using the Beacon designer software v.8 (Premier Biosoft) and obtained from IDT (Coralville, IA). The reference gene for normalization was Gapdh for the heart. In the adipose tissue, reference genes (Rpl22 and Actb) were determined according to the MIQE guidelines (Minimum Information for Publication of Quantitative Real-Time PCR Experiments). 12 The qPCR was performed with SYBR-Green reaction mix (BioRad, Hercules, CA). The qPCR conditions consisted of an initial denaturation at 95°C for 3 minutes, followed by 40 cycles of amplification, with each cycle consisting of 95°C for 10 seconds, and 60°C (heart) or 57°C (adipose tissue) for 30 seconds.
Western Blotting
Tissues from WT and Adcy9
Gt/Gt mice were lysed with TissueLyser II (QIAGEN) in buffer containing (in mM): Tris base, 50; NaCl, 125; EDTA, 0.1; EGTA, 0.1; sodium dodecyl sulfate (SDS) 0.1%; sodium deoxycholate, 0.5%; and IGEPAL, 1% protease inhibitor cocktail (Sigma-Aldrich, Ontario, Canada), on ice. The protein concentration was assessed by Lowry assay. Proteins were loaded and migrated in SDS-polyacrylamide gel for 90 minutes at 100 V. Proteins in gel were then transferred overnight on a polyvinylidene difluoride (PVDF; BioRad) membrane. Membranes were blocked using TBST 5% nonfat dried milk. For detection of LDL receptor in livers from mice infected with AAV8-Pcsk9 D377Y or control mice injected with saline, the membranes were then incubated with a goat primary antibody targeting mouse LDL receptor (Novus Biologicals, AF2255, Littleton, CO) at 1/5000 dilution, in TBST 1% nonfat dried milk at 4°C overnight. A rabbit secondary antigoat antibody (Abcam, ab6741, Cambridge, MA) was incubated at 1/5000 for 60 minutes at room temperature in TBST 3% BSA. For detection of ADCY9 in dorsal skeletal muscle, antiserum against ADCY9 was produced by immunizing rats (Thermo Fisher Scientific) with C-terminal mouse ADCY9 peptide 1313-REPVKAEERFPFGKAIEKD-1331 (NP_033754.2) conjugated with keyhole limpet hemocyanin. Membranes were incubated with rat serum diluted 1/500 in TBST, and then with goat antirat secondary antibody (ThermoFisher, cat # 31475), diluted 1/10000 in TBST containing 3% BSA. Detection was performed using Western Lightning ECL Pro (Perkin Elmer, Waltham, MA).
Determination of Plasma Cholesterol Concentration, Lipoprotein Profile, and Plasma PCSK9
Blood samples were collected in EDTA-coated tubes and plasma was separated by centrifugation (2000g, 10 minutes) and conserved at -80°C until analysis. Total cholesterol was quantified by colorimetric enzymatic assay (Wako Diagnostics, 999-02601, Richmond, VA), and measured at 600 nm in 96-well black microplates with flat bottoms, according to a micromethod used in our laboratory. To determine the lipoprotein profile, blood samples were pooled from 5 mice per group and a fast protein liquid chromatography size fractionation on Sepharose was performed by a specialized lipidomics core facility (University of Alberta, Edmonton, AB). PCSK9 concentration in plasma was determined using an ELISA kit targeting mouse PCSK9 (Cyclex Co, #CY-8078, Japan).
En Face Quantification of Aortic Atherosclerotic Lesions
Atherosclerosis lesions were quantified on whole aorta dissected en face. Aortas were fixed in 4% paraformaldehyde overnight, then stained with a 0.7% solution of Oil Red O (Sigma-Aldrich) for 1 hour, and then counterstained with Nuclear Fast Green at 0.05% (Sigma-Aldrich, F7258) to optimize contrast. Images were captured using a Leica Microsystem (Concord, Ontario, Canada) stereomicroscope with digital camera (MC170 HD, Leica Microsystem). Atherosclerotic lesions were quantified from the aortic root down to the iliac artery bifurcation using Image-Pro Premier 9.2 (Media Cybernetics, Inc, Rockville, MD). Percent atherosclerotic lesion area was expressed as the percentage of the intima area presenting Oil Red O staining.
Atherosclerotic Lesion Cross-Sectional Quantification in the Aortic Root
The base of the heart was embedded in OCT compound and sliced in 10 µm sections before fixation with 10% cold formalin for 5 minutes and then rinsed twice with deionized water. Slides were immersed twice in 100% propylene glycol for 5 minutes. Aortic roots were stained with a 0.7% Oil Red O solution for 48 hours at room temperature. Afterward, slides were successively immersed in 100% propylene glycol, 85% propylene glycol solution and deionized water baths, using agitation. Slides were counterstained with a hematoxylin
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solution for a few seconds, rinsed, and then mounted using an aqueous medium. Atherosclerosis lesions were quantified at regular distances from the base of the aortic sinuses to 500 μm more distally in the aortic root. Images were obtained by microscope and quantified by Image-Pro Premier 9.2.
Atherosclerotic Lesion Quantification in the Brachiocephalic Artery
The presence of plaques, fibrin, red blood cells, and break in the plaque cap was determined in the brachiocephalic artery. All solutions used for staining were from EMS (Hatfield, PA) except for phosphotungstic acid that was from Sigma-Aldrich. Six micrometer-thick sections (6 μm), taken from paraffinembedded brachiocephalic artery, were stained according to the Carstairs' method with modification as described previously. 13 After rehydration, sections were incubated in 5% ferric ammonium sulfate solution for 5 minutes and rinsed with tap water. Sections were then stained with Mayer hematoxylin solution for 5 minutes and rinsed with tap water. Additional stainings were performed with picric acid orange G for 1 hour and Ponceau-Fuchsin for 5 minutes before rinsing with distilled water for each staining. Muscle tissue was differentiated from other structures with 1% phosphotungstic acid for 3 minutes before rinsing with distilled water. Final staining for collagen was performed with Anilin Blue (2.5%, 2 minutes) before dehydration clearing with xylene and mounting in Permount (Thermo Fisher Scientific, Toronto, Ontario, Canada). We scored the sections for presence of plaques, fibrin deposition at the surface of the plaque, and breaks in the plaque cap. To be scored positively, a mouse needed to show the feature of interest in 2 sections separated by 48 μm.
Immunofluorescent Detection of CD68-Positive Macrophages (Foam Cells) and Their Proliferation in the Aortic Root
The base of the heart was embedded in optimal cutting temperature compound and 10 µm sections were cut with a cryostat. Slides were incubated in PBS to remove the optimal cutting temperature compound and then immersed in 4% paraformaldehyde (pH 7.4) for 20 minutes. After fixation, slides were washed in PBS. Permeabilization, blocking, and antibody incubation were performed in a Tris solution (in mM): Tris-base, 50; NaCl, 150; BSA, 1%; Triton X-100, 0.4%; and fetal bovine serum, 20%, at pH 7.4. Rat antibody against CD68 was diluted 1/200 (BioRad, #MCA19557) and rabbit antibody against Ki67 was used at 1 μg/mL (Abcam, #ab15580). For determination of CD68-positive cell accumulation in the atherosclerotic lesions, CD68 was visualized using goat antirat antibody labeled with Alexa-647 (Thermo Fisher Scientific, # cat A-21247). For costaining with Ki67, CD68 was visualized with goat antirat antibody labeled with Alexa-568 (Thermo Fisher Scientific, #A11077), and Ki67 was visualized with a goat antirabbit antibody labeled with Alexa-647 (Thermo Fisher Scientific, #A-27040). The nuclei were counterstained with 4',6-Diamidino-2-Phenylindole. Images were acquired with a confocal microscope (LSM 710, Zeiss, Peabody, CA). Imaging quantifications were performed with Image-Pro Premier 9.2 from 3 sections of the aortic root. Accumulation of CD68-positive foam cells was quantified as percent of the total lesion area from 3 aortic root sections. Cells were considered positive for Ki67 if the staining colocalized with 4',6-Diamidino-2-Phenylindole. To evaluate proliferation of CD68-positive foam cells, double positive Ki67/ CD68 cells were counted.
Splenocyte Adhesion to Native Endothelium and Quantification of Adhesion Molecule Expression
Splenocyte adhesion to native aortic endothelium from atherosclerotic mice was evaluated, as described previously, with some modifications.
14 Briefly, fresh aorta and spleen were isolated. The aorta was sectioned in 2 segments of similar surface to separate the proximal part, including the arch, from the more distal portion. Both segments were pinned down in a Petri dish, the intima facing up. Splenocytes at a concentration of 10 6 cells/250 μL from WT and Adcy9
Gt/Gt mice were isolated and radioactively labeled with 100 μCi of 51
Cr. The proximal aortic segment was incubated with histamine 10 μmol/L for 10 minutes before the adhesion assay and the distal segment was used as control. After histamine wash-out, aortic intima was exposed to 51 Cr-loaded splenocytes. Test experiments showed similar adhesive properties between the proximal and distal aortic segments (data not shown). The number of leukocytes adherent to the endothelium was expressed per surface area of the segment (adherent cells/mm 2 of endothelium surface area). Splenocyte cell surface expression of CD18 (#553293), CD62L (#562910), and CD162 (#562806, all from BD Biosciences, Mississauga, Ontario, Canada) was determined using an LSRII flow cytometer (BD Instruments, San Jose, CA). All data were collected and analyzed with FACSDiva software v.8.
Nonesterified Fatty Acid Measurement in Plasma
Plasma nonesterified fatty acid concentration was measured using the HR Series NEFA-HR (2) (Wako Diagnostics) assay according to the manufacturer's recommended procedure.
Assessment of Endothelial Function in the Femoral Artery with Pressurized Arteriography
Vascular reactivity was studied in the femoral artery of untreated and atherosclerotic mice, as already described. 15 Femoral arteries, 250 to 350 μm in diameter, were bathed in physiological saline solution of the following composition (mM): NaCl, 130; KCl, 4.7; CaCl 2 , 1.6; MgSO 4 , 1.17; NaHCO 3 , 14.9; KH 2 PO 4 , 1.18, EDTA, 0.026, and glucose 10.0, and pressurized to 80 mm Hg. Physiological saline solution was bubbled with a gas mixture containing 12% O 2 , 5% CO 2 , and 83% N 2 . Before construction of concentration-response curves to vasodilator or shear stress, segments were preconstricted with phenylephrine at a concentration from 10 -6 mol/L to 10 -5 mol/L. ACh and SNP were used for assessment of endothelium-dependent and endothelium-independent vasodilatation, respectively. SNP curves were created with endothelium-denuded segments. To study the role of endothelial cell signaling, segments were incubated with the nitric ORIGINAL RESEARCH ARTICLE oxide synthase blocker L-NNA (10 -4 mol/L, Sigma-Aldrich), the cyclooxygenase blocker meclofenamate (10 -6 mol/L, SigmaAldrich), or a cocktail of endothelial potassium channel blockers, TRAM34 (10 -5 mol/L, Tocris Bioscience, Minneapolis, MN) and apamin (10 -7 mol/L, Tocris Bioscience), and the curves were constructed in presence of the blocker. Shear stress was calculated using the following equation: t=4ηQ/πr 3 , where t is the shear stress (dyn/cm 2 ), η the viscosity [0.009 Poise], Q the flow rate (ml/s) through the lumen, and r the inside radius (cm). Vasodilatation is expressed as the change (%) in diameter normalized to the maximal passive diameter obtained with SNP in absence of calcium.
In Situ Hybridization
In situ hybridization was performed according to the manufacturer's recommended procedure (Advanced Cell diagnostic, Hayward, CA). Staining was performed on 6 µm-thick sections of paraffin-embedded femoral artery or aortic root. Sections were counterstained with hematoxylin. We observed that the signal for Adcy9 was specific by comparing tissue sections from Adcy9
Gt/Gt and WT mice (data not shown). Adcy9 probe was Mm-Adcy9 targeting nucleotides 1522 to 2502 of NM_009624.3. Probe for the bacterial gene dapB was used as a negative control.
Quantification of Whole Body Adipose Tissue Volume by Magentic Resonance Imaging
Whole mouse magnetic resonance imaging was performed in the prone position on a 30-cm 7T horizontal MR scanner (Agilent, Palo Alto, CA), with a 12-cm inner diameter gradient coil insert, gradient strength 600 mT/m, rise-time 130 µs, and an Agilent quadrature transmit/receive birdcage coil with an internal diameter of 38 mm. A pressure transducer for respiratory monitoring and gating (used for shimming) was placed under the abdomen near the sternum. Anesthesia was maintained with 2.0 to 3.0% isoflurane in pure oxygen to target a respiration rate between 80 and 120 BPM, while heart rate and oxygen saturation were monitored with a pulse oximeter on the right hindpaw, and body temperature was maintained at 37.0°C with a rectal probe and a warm air fan (SA Instruments, Stony Brook, NY). A 3D TFISP sequence was used to image the whole mouse (except the tail), with isotropic voxels and FOV 70×36×36 mm, matrix size 256×192×192, resolution 270×190×190 µm, an asymmetrical 500 µs pulse with 30 degrees flip angle, TR/TE=4.8/2.4 ms, 83 kHz acquisition bandwidth, and 8 frequency-shifted scans reconstructed by squareroot-of-sum-of-squares, for an acquisition time of 24 minutes. 16 Mouse fat was manually quantified using ITK-SNAP. 17 
Telemetry for ECG Recording
Telemetry was used to monitor and record ECG in conscious free-moving unanesthetized WT, Adcy9
Gt/Gt mice, CETPtgAdcy9 WT , and CETPtgAdcy9
Gt/Gt mice. Mice were equipped with an ECG transmitter (ETA-F10, DSI, St Paul, MN) for mice, and electrodes were placed subcutaneously on the abdomen in a conventional lead II position. 18 Recordings were performed continuously at 1 KHz per channel with IOX (version 2.8.0.17, EMKA Inc) 10 days postsurgery. ECGs were analyzed for heart rate variability (HRV) according to the guide by Thireau et al, 19 and with the software ECG Auto (v3.3.0.25, EMKA Inc). Periods containing 1500 beats for day time (6 am to 6 pm) and night time (6 pm to 6 am) were analyzed. Data were analyzed to extract the time domain parameters RR interval and pNN (6) , the latter representing the percentage of RR intervals exceeding preceding ones by 6 ms or more and reflects parasympathetic nervous system activity. 19 
Body Weight Measurement and Feed Efficiency
Body weight was measured every week from the week of infection with AAV8-Pcsk9 D377Y , for a total of 16 weeks. Feed efficiency, the ratio of the weight gain to the caloric intake (g/100 kcal), was calculated for a total of 8 weeks during the atherogenic diet.
In Vivo β-Adrenergic-Stimulated Lipolysis
Experiments were performed in mice treated for 7 weeks with the atherogenic diet. Isoproterenol 0.3 mg/kg was injected IP and blood was collected from the tail vein. Plasma glycerol was measured at baseline, 15, and 30 minutes following isoproterenol injection using Free Glycerol Colorimetric/ Fluorometric Assay kit from Biovision (#K630-100, Biovision, Milpitas, CA), according to the manufacturer's instructions.
Histology for Adipose Tissue
Sections of paraffin-embedded epididymal fat and brown interscapular fat were stained with hematoxylin and eosin and imaged with a BX41 microscope (Olympus, Richmond Hill, Ontario, Canada)
Statistical Analysis
Descriptive statistics for continuous variables were presented using the mean and standard error of the mean. For continuous variables assessed at a single time point, groups of mice were compared using Student t-tests, ANOVA models, or Kruskal-Wallis nonparametric tests depending on the distribution of the variables. Categorical variables were compared across groups using Fisher exact tests. For variables assessed at different time points or under various conditions within mice, 2-way or 3-way repeated measures ANOVA models were used. These models included within and between factors, as well as the corresponding interaction terms. Basic assumptions were always checked before analysis. All tests were conducted at the 0.05 significance level without correction for multiple testing with SAS version 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Adcy9 Inactivation Protects Against Atherosclerosis
First, we characterized the effect of the Adcy9
Gt modified target locus on Adcy9 expression in Adcy9
Gt/Gt mice. Using reverse transcription-qPCR, we demonstrated that Adcy9 mRNA expression in the heart was decreased by 50% in Adcy9
WT/Gt mice, and by at least 90% in Adcy9
Gt/Gt mice compared to WT ( Figure IA in the online-only Data Supplement). In the skeletal muscle, where the ADCY9 gene has been reported to be highly expressed, 20, 21 we observed that protein expression was abolished in Adcy9
Gt/Gt mice compared to WT ( Figure IA in the online-only Data Supplement). Then, we infected WT and Adcy9
Gt/Gt mice with AAV8-Pcsk-9 D377Y to induce hypercholesterolemia. One week after infection, and before the start of the atherogenic diet, plasma PCSK9 concentration was markedly increased from 0.1 μg/mL to 17.9±3.5 μg/mL in WT and 26.6±7.5 μg/mL in Adcy9
Gt/Gt mice. PCSK9 concentrations increased to 71.0±19.1 μg/mL in WT and 90.8±20.1 μg/ mL in Adcy9
Gt/Gt mice after 8 weeks of the atherogenic diet, where they stayed almost stable at 12 weeks ( At sacrifice, aortas showed 11.3±2.1% of the surface of the intima covered with atherosclerotic lesions in WT mice, compared to 3.8±0.6% in Adcy9
Gt/Gt mice (P<0.01, Figure 1A ), a reduction of 65%. Cross-sectional quantification showed a numeric reduction of plaque area all along the aortic root by Adcy9 inactivation (P=0.07 at 500 µm, Figure 1B) . Brachiocephalic arteries are the site in mice where plaques are more complex and prone to rupture, 22 Figure 1C shows that all WT animals had plaques in the brachiocephalic arteries in contrast to Adcy9
Gt/Gt mice (100%, versus 50%, P<0.05). The plaques in WT mice also presented more frequently fibrin deposits at their surface (P=0.06) and cap ruptures compared to Adcy9
Gt/Gt mice ( Figure 1C ).
Adcy9 Inactivation Reduces CD68-Positive Macrophage (Foam Cell) Accumulation and Proliferation in Atherosclerotic Lesions
CD68-positive foam cells, a key constituent of atherosclerotic plaques, represented 19.0±1.9% and 11.4±2.1% of the lesion area in WT and Adcy9
Gt/ Gt mice, respectively (P<0.05, Figure 2A ). This was confirmed using flow cytometry, with a reduction in CD11b/CD68-positive cells in the intima of the aorta of Adcy9 Gt/Gt mice compared to WT (data not shown). In addition, in situ hybridization showed Adcy9 expression in atherosclerotic lesions at sites of foam cell accumulation ( Figure 2B ). Immunofluorescence detection of Ki67 revealed that proliferation of CD68-positive foam cells was significantly decreased in Adcy9
Gt/Gt compared to WT (P<0.05, Figure 2C ). Ex vivo flow cytometry showed that Adcy9 inactivation did not change the blood concentration of total monocytes and their classical, intermediate and nonclassical subpopulations (Table in the online-only Data Supplement). Migration capacity of bone marrow-derived monocytes toward CCL2 was also unchanged (data not shown).
Adcy9 Inactivation Potentiates Endothelial Function
Endothelial-dependent vasodilatation to ACh in untreated animals (no AAV8-Pcsk9 D377Y and no atherogenic diet) was potentiated in the femoral arteries of Adcy9
Gt/Gt mice compared to WT (P<0.01, Figure 3A) ; in contrast, endothelial-independent vasodilation to the nitric oxide donor SNP was similar in both groups ( Figure 3A) . Adcy9 inactivation also potentiated endothelial-dependent vasodilatation in response to increased shear stress (10 dynes/cm 2 ) compared to WT (42.3±7.1% versus 28.2±6.3%, P=0.13; Figure 3B ). In femoral arteries from atherosclerotic animals (AAV8-Pcsk9 D377Y and atherogenic diet), both endothelial-dependent (ACh-induced) and endothelial-independent vasodilatation were increased in Adcy9
Gt/Gt mice compared to WT (P<0.05; Figure 3C ).
In order to assess the mechanisms that may be involved in reduced foam cell accumulation in response to Adcy9 inactivation, a cell adhesion assay on native endothelium was used using radioactively-labeled splenocytes, as a source of immune cell populations, and aorta from atherosclerotic mice. Basal adhesion of splenocytes to the endothelium was numerically reduced in Adcy9
Gt/Gt mice (375±68 cells/mm 2 , n=5) compared to WT (734±119 cells/mm 2 , n=5, P=0.07). Histamine activation of the endothelium significantly increased splenocyte adhesion compared to baseline (nonstimulated conditions) in WT mice ( Figure 3D ) (1411±313 cells/mm 2 , n=5, P<0.05). In contrast, adhesion of splenocytes to the endothelium was not significantly modified by histamine compared to baseline in Adcy9
Gt/Gt mice, and hence, was significantly reduced compared to WT (539±207 cells/mm 2 , n=5,
P<0.05 between Adcy9
Gt/Gt and WT mice after stimulation by histamine). The expression of cell adhesion molecules CD18, CD162, and CD62L on the surface of splenocytes was also investigated by flow cytom- Selective pharmacological blockade of the signaling pathways responsible for endothelial-dependent vasodilatation 23 was then used to identify the mechanism responsible for the improvement observed in Adcy9
Gt/ Gt mice. The nitric oxide synthase blocker L-NNA inhibited significantly ACh-induced vasodilatation both in WT and Adcy9
Gt/Gt mice (P<0.01), but flow-mediated vasodilatation was numerically reduced only in
Adcy9
Gt/Gt mice ( Figure 3E ). In contrast, the cyclooxygenase (responsible for production of prostacyclin) blocker meclofenamate or the cocktail of endothelialdependent hyperpolarization blockers (TRAM-34 and apamin), inhibited ACh-induced endothelial-dependent vasodilatation in Adcy9
Gt/Gt mice (P<0.01 for both pathways, Figure 3F ), but not in WT mice.
Gt/Gt mice are systemically inactivated for Adcy9, making it difficult to identify a direct role in vascular tissue that could be associated with the observed Gt/Gt mice.
B, Aortic roots from WT and Adcy9
Gt/Gt mice were sectioned and stained with Oil Red O. Oil Red O-stained lesion area was quantified from the base of aortic valve sinus to 500 µm more distally in the aortic root. Images are representative sections 100 µm down from the base of the sinus. Scale bar: 200 µm. C, Brachiocephalic arteries were sectioned and stained using the Carstairs' method. 15 
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potentiated endothelial function. Therefore, Adcy9 mRNA expression was studied by in situ hybridization on histological sections and was demonstrated in the femoral artery wall. Specificity of the Adcy9 mRNA signal was confirmed by absence of dots with the negative control probe ( Figure 3G ).
Adcy9 Inactivation Increases Body Weight and Adipose Tissue Volume
Adcy9
Gt/Gt mice gained more weight than WT animals from weeks 3 to 16 of atherogenic diet, to reach weights of 45.1±2.4 g and 33.5±1.2 g, respectively (P<0.01; Figure 4A ). Magnetic resonance imaging performed at week 14 showed that Adcy9
Gt/Gt mice presented more adipose tissue than WT ( Figure 4B) , with a doubling of total body adipose tissue volume in Adcy9 Figure 4C ). This increase was confirmed by the larger inguinal, perirenal, epididymal, and interscapular fat depots ( Figure 4D ). Histological sections showed that Adcy9 inactivation resulted in hypertrophic adipocytes in epididymal white adipose tissue and larger lipid droplets in interscapular brown adipose tissue ( Figure 4E ). No significant change in blood glucose or insulin concentrations was observed in response to the atherogenic diet and increased fat deposits (data not shown).
Adcy9 Inactivation Modulates Autonomic Nervous System Activity
Given the differences in weight gain between Adcy9
Gt/Gt and WT mice, food intake and feed efficiency were evaluated. With the atherogenic diet, food intake was 3.7±0.1 g/d in Adcy9
Gt/Gt mice and 3.0±0.1 g/d in WT (P<0.01; Figure 5A ). Feed efficiency, defined as the ratio of weight gain over energy intake, was significantly increased in Adcy9
Gt/Gt mice (1.2±0.1 g/100 kCal) compared to WT (0.61±0.07 g/100 kCal, P<0.01; Figure 5A ). This indicates that the control of energetic balance, which is dependent on the ANS, is modified by Adcy9 inactivation. Therefore, we evaluated ANS activity by measuring HRV by telemetry in WT and Adcy9
Gt/Gt mice. The RR interval was increased in Adcy9
Gt/Gt mice (nocturnal RR, 135±5 ms) compared Figure 5B ). Nocturnal heart rate was lower in Adcy9
Gt/Gt mice (452±17 bpm) compared to WT (492±16 bpm, P<0.05). Increased parasympathetic activity was also demonstrated by pNN (6) , representing the percentage of RR intervals exceeding preceding ones by 6 ms or more, 19 which was higher during the night period in Adcy9
Gt/Gt mice (21.6±2.4%) compared to WT (15.5±2.2%, P=0.0572; Figure 5C ).
Adcy9 Inactivation-Induced Atheroprotection is Lost in Mice Expressing CETP
In order to study the modulation of Adcy9 inactivation effects by CETP, we repeated the experiments in the presence of CETP by crossing transgenic mice for the human CETP minigene (CETPtgAdcy9 WT ) with Adcy9
Gt/Gt mice to obtain animals with CETP and homozygous for the inactivated allele of Adcy9 (CETPtgAdcy9 Gt/Gt ). We then submitted both types of mice (CETPtgAdcy9 WT and CETPtgAdcy9
Gt/Gt ) to the previously described atherogenic protocol (involving AAV8-Pcsk9 D377Y injection and atherogenic diet). CETPtgAdcy9
WT and CETPtgAdcy9
Gt/Gt mice developed similar atherosclerotic lesions that covered 12.6±1.7% and 8.2±1.8% of the intima area, respectively (P>0.05; Figure 6A ). Figure 6B compares percentage of lesion area in the whole aorta in WT, Adcy9
Gt/Gt , CETPtgAdcy9 WT , and CETPtgAdcy9
Gt/Gt to emphasize the absence of atheroprotection in CETPtgAdcy9
Gt/Gt mice compared 
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to Adcy9 Gt/Gt mice. These results indicate that Adcy9 does not significantly affect atherosclerosis development in presence of CETP.
Adcy9 Inactivation-Induced Endothelial Function Protection is Lost in Mice Expressing CETP
Given the loss of Adcy9 inactivation-induced atheroprotection when the CETP gene is introduced, we studied vasodilatation to ACh and SNP in femoral arteries from atherosclerotic CETPtgAdcy9
Gt/Gt ( Figure 7 ). Adcy9 inactivation no longer modified endothelial-dependent vasodilatation in response to ACh when CETP was present ( Figure 7) . However, SNP-induced vasodilatation remained potentiated by Adcy9 inactivation in mice with CETP (P<0.01 for CETPtgAdcy9
Gt/Gt versus CETPtgAdcy9 WT ; Figure 7 ). These results suggest that the atheroprotective effect of Adcy9 inactivation in the absence of CETP is associated with their role in the regulation of endothelial function.
Adcy9 Inactivation-Induced Gains in Body Weight and Adipose Tissue Volume are Lost in Mice Expressing CETP
We then investigated the effect of Adcy9 inactivation on body weight change in mice expressing CETP during the atherogenic treatment. CETPtgAdcy9
WT and CETPtgAdcy9 Gt/Gt mice had similar progression of body weight on atherogenic treatment ( Figure 8A ; Figure 8B ). These results demonstrate that Adcy9 and CETP also interact in the regulation of weight and adiposity.
Adcy9 Inactivation-Induced Effects on Feed Efficiency and HRV Are Differentially Modified in Mice Expressing CETP
Similar to mice without CETP, Adcy9 inactivation increased daily food intake in CETPtgAdcy9
Gt/Gt mice (3.48±0.08 g) compared to CETPtgAdcy9 WT (3.12±0.05 g, P<0.01; Figure 8C ). In contrast, feed efficiency was not significantly modified by Adcy9 inactivation in CETP mice (CETPtgAdcy9 WT , 0.90±0.1 g/100kcal, CETPtgAdcy9
Gt/Gt , 0.79±0.12 g/100kcal, P>0.05; Figure 8C ). Moreover, Adcy9 inactivation similarly increased nocturnal RR interval in CETPtgAdcy9
Gt/Gt (134±2) compared to CETPtgAdcy9 WT (122±5 ms, P=0.07; Figure 8D ), as observed in mice without CETP. Also, nocturnal pNN(6) was increased in CETPtgAdcy9
Gt/Gt (24.6±1.3%) compared to CETPtgAdcy9 WT (13.5±2.8%, P<0.01; Figure 8E ), as was observed in mice without CETP. These results suggest that Adcy9 control of different aspects of ANS activity (reflected by feed efficiency and HRV) is differentially affected by CETP activity.
Decrease in β-adrenergic-Stimulated
Lipolysis is Associated With Adcy9-Mediated Regulation of Adipose Tissue Volume
After 12 weeks of atherogenic diet, Adcy9 inactivation increased significantly nonesterified fatty acid in Adcy9
Gt/Gt mice compared to WT (P<0.01;. Figure  IIIA in the online-only Data Supplement), but not in CETPtgAdcy9
Gt/Gt versus CETPtgAdcy9 WT mice. The increase in adipose tissue volume in Adcy9
Gt/Gt mice is thus associated with an increase in plasma concentration of nonesterified fatty acid. Adcy9 mRNA expression was detected in WT and CETPtgAdcy9 Gt/Gt compared to WT, 15 minutes (WT, 184±30%; Adcy9
Gt/Gt , 48±9%, P<0.01) and 30 minutes (WT, 164±10%; Adcy9
Gt/Gt , 87±14%, Gt/Gt mice. Heart rate was measured for 12-hour periods during the day and night-time. C, Heart rate variability analysis in the time domain. pNN (6) is the percentage of RR intervals exceeding preceding ones by 6 ms or more and reflects parasympathetic nervous system activity. WT indicates wild type. **P<0.01.
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P<0.01; Figure 
DISCUSSION
The results of this study show that, in mice that naturally lack CETP activity, ADCY9 inactivation protects against atherosclerosis, reduces macrophage accumulation and proliferation in the arterial wall, improves endothelial function, increases feed efficiency, and modulates ANS activity. These effects of ADCY9 inactivation are not seen in the presence of CETP, and the results therefore support the interactions between ADCY9 and CETP activity observed in clinical studies.
Our findings support the results from the dal-Outcomes and dal-Plaque-2 clinical trials, 7, 24 in which a pharmacogenomic interaction was observed between ADCY9 and CETP activity. Indeed, the genotype at rs1967309 in the ADCY9 gene determined responses to the CETP inhibitor dalcetrapib, but not to placebo. These responses included clinical events (coronary heart disease death, myocardial infarction, stroke, hospitalization for unstable angina, and coronary revascularization) and carotid atherosclerosis changes on imaging. One limitation of our animal model is that the human genetic polymorphisms in ADCY9 determining responses to dalcetrapib are not conserved in the mouse genome. An additional limitation is that there are likely differences in ADCY9 expression and activity between patients and the mouse model. Contrary to the effects observed in patients, our results (unpublished), and those from others, 25 demonstrate that dalcetrapib significantly, and paradoxically, decreases HDL-C in mice transgenic for human CETP. Therefore, CETPtg mice could not be used as a model to study the effects of dalcetrapib on atherosclerosis development. Consequently, we used a genetic model to determine the effects of Adcy9 inactivation in the absence or presence of CETP. Given that the clinical results mentioned above did not reveal any sex-related differences, the current study only involved male mice, although a gender effect in mice cannot be excluded.
Our results offer insights into the underlying mechanisms for the interactions between ADCY9 and CETP activity in patients. The reduction in atherosclerosis caused by ADCY9 inactivation in the absence of CETP was related to the reduced accumulation of CD68-positive macrophages in the arterial wall, which in turn was due, in part, to their decreased proliferation. The reduced accumulation and proliferation of macrophages are concordant with the ADCY9 genotype-dependent changes in the inflammatory biomarker C-reactive protein that were previously reported with dalcetrapib. 7 Of note, Adcy9 ex- ORIGINAL RESEARCH ARTICLE pression has previously been associated with regulation of inflammatory processes, such as chemoattraction. 26, 27 In addition, inhibition of macrophage Adcy9 expression was previously shown to decrease IL-6 expression. 28 Because changes in endothelial cell activation and functions may be responsible for these observations and endothelial dysfunction is one of the earliest event in atherosclerosis initiation, 29 we evaluated endothelium-dependent vasoreactivity and immune cell adhesion.
Both endothelial-dependent and endothelial-independent vasodilatations were improved in mice inactivated for Adcy9 in the absence of CETP when submitted to the atherogenic protocol. This suggests that the protection offered by Adcy9 inactivation extends to vascular smooth muscle cells. Importantly, Adcy9 inactivation also protected aortic endothelium of Adcy9
Gt/Gt mice (compared to WT) from adhesion of immune cells. In light of these differences in splenocyte adhesion to the endothelium of Adcy9
Gt/Gt and WT mice and lack of changes in cell adhesion molecules on the surface of splenocytes, it can be concluded that the protective effect of Adcy9 inactivation on the endothelium (reducing adhesion of immune cells) contributes to reduced foam cell accumulation in the arterial wall. Gt/Gt mice C, Daily food intake (left) and feed efficiency (right) in CETPtgAdcy9 WT and CETPtgAdcy9 Gt/Gt mice treated with the atherogenic protocol. D, ECG were recorded by telemetry in CETPtgAdcy9
WT and CETPtgAdcy9 Gt/Gt mice. Heart rate was measured for 12-hour periods during the day and night-time. E, HRV analysis in the time domain. pNN(6) is the percentage of RR intervals exceeding preceding ones by 6 ms or more and reflects parasympathetic nervous system activity. CETP indicates cholesteryl ester transfer protein; HRV, heart rate variability; and WT, wild type. *P<0.05. **P<0.01.
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To show that effects on endothelial function precede atherosclerosis development in Adcy9
Gt/Gt mice, we evaluated animals not exposed to the AAV8-Pcsk9 D377Y injection/atherogenic diet protocol, and demonstrated enhanced endothelial-dependent vasodilatation of femoral arteries. In order to determine the endothelial signaling pathways responsible for this increased vasorelaxation, selective pharmacological blockade was used. Blockers of the nitric oxide, cyclooxygenase (responsible for the production of prostacyclin), and endothelial-dependent hyperpolarization pathways administered separately all caused greater inhibition of vasodilatation in Adcy9
Gt/Gt mice compared to WT animals. These pharmacological results demonstrate that all 3 of these activated endothelial cell signaling pathways are involved in the benefits of Adcy9 inactivation on endothelial function in the absence of CETP activity. Given that vasorelaxation was evaluated in femoral arteries and the main site of atherosclerosis development in mice is the aorta, it remains uncertain whether these endothelial signaling pathways are associated with the atheroprotection induced by Adcy9 inactivation.
Adcy9
Gt/Gt mice (without CETP) weighed approximately 12 g more than WT animals at the end of follow-up, and this was caused mostly by increased adipose tissue volume. There was no associated change in blood glucose or insulin concentrations, suggesting that the weight gain in response to Adcy9 inactivation does not modify insulin sensitivity. The increase in adipose tissue volume was associated with reduced β-adrenergic-induced lipolysis and decreased expression of β-adrenoceptors in Adcy9
Gt/Gt mice compared to WT. This is concordant with the ADCY9 rs1967309 genotype-dependent changes in weight that were in the opposite direction to atherosclerosis-related outcomes in dalcetrapib-treated patients of the dal-Outcomes trial. 5 Additional ADCY9 and ADCY3 polymorphisms have also been associated with obesity phenotypes in other clinical studies. 30 Feed efficiency was significantly increased in Adcy9
Gt/Gt mice, suggesting that changes in ANS activity (which controls energetic balance 31, 32 ) might be involved. In addition, the cardiac RR interval was longer (hence the lower heart rate) in Adcy9
Gt/Gt than in WT mice. To confirm this change in ANS activity, we evaluated the pNN(6) time-domain parameter of HRV. 19 In accordance with cardiac RR and heart rate results, the increase in pNN(6) suggests increased (beneficial) parasympathetic activity in Adcy9
Gt/Gt mice compared to WT animals.
Given that ADCY9 activity is regulated by G-protein, coupled receptors including the β-adrenergic receptor, additional work (including with pharmacological blockers) will be necessary to determine whether sympathetic tone is also modified in Adcy9
Gt/Gt mice. Changes in ANS activity could be highly relevant to our study findings: increased parasympathetic tone may have contributed to reduced macrophage accumulation and proliferation through the well-known cholinergic anti-inflammatory pathway. 33 Furthermore, altered sympathetic drive could explain the apparent paradox of opposite changes in weight and in cardiovascular responses.
The loss of the above-mentioned effects of ADCY9 inactivation on atherosclerosis, endothelial function, and weight when the CETP gene was introduced in mice is a key finding of the current study, which is concordant with the absence of ADCY9 genotype-dependent differences in the placebo group of the dalOutcomes and dal-Plaque-2 trials. 5, 7 We have shown that CETP has differential effects on Adcy9 regulation of different aspects of ANS activity. Indeed, the effects of Adcy9 inactivation on feed efficiency and weight (ie, control of energetic balance) were abolished by CETP, but those on heart rate and HRV were not. Expressed differently, the absence of increase in feed efficiency in response to Adcy9 inactivation in CETPtg mice, unlike animals lacking CETP, confirms that ANS activity is affected by the interplay between Adcy9 and CETP activity. The effect of CETP activity on Adcy9-mediated regulation of adipose tissue could be dependent on the observed effect of CETP on Adcy9 inactivation-induced reduced expression of lipolytic genes (β-adrenoceptors and lipases). Furthermore, the modulation of ANS activity by ADCY9 inactivation, in the absence of CETP, raises the intriguing possibility of central nervous system effects of CETPinduced changes in lipoprotein metabolism. Accordingly, we have recently observed that plasma-borne fluorescently-labeled HDL crosses the blood-brain barrier to reach the mouse brain ( Figure IV in the online-only Data Supplement).
In conclusion, our study demonstrates that Adcy9 inactivation protects against atherosclerosis, but only in the absence of CETP activity. This atheroprotection may be explained by decreased macrophage accumulation and proliferation in the arterial wall, improved endothelial function and altered ANS activity. The ongoing Dal-GenE pharmacogenomics-guided clinical trial is testing whether patients with coronary disease and the favorable ADCY9 genotype will benefit from CETP inhibition with dalcetrapib, in terms of improved clinical cardiovascular outcomes.
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